{"authors": [["Coulombe", "Katherine", "K", "Facult\u00e9 de Pharmacie, Pavillon Ferdinand-Vandry, 1050, Avenue de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada; Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada; OptiNutriBrain International Associated Laboratory (NutriNeuro France-INAF Canada), Canada."], ["Kerdiles", "Olivier", "O", "Facult\u00e9 de Pharmacie, Pavillon Ferdinand-Vandry, 1050, Avenue de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada; Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada; OptiNutriBrain International Associated Laboratory (NutriNeuro France-INAF Canada), Canada."], ["Tremblay", "Cyntia", "C", "Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada."], ["Emond", "Vincent", "V", "Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada."], ["Lebel", "Manon", "M", "Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada; D\u00e9partement de Psychiatrie & Neurosciences, Facult\u00e9 de M\u00e9decine, Pavillon Ferdinand-Vandry, 1050, Ave de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada."], ["Boulianne", "Anne-Sophie", "AS", "Facult\u00e9 de Pharmacie, Pavillon Ferdinand-Vandry, 1050, Avenue de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada."], ["Plourde", "M\u00e9lanie", "M", "Centre de Recherche sur le Vieillissement, Universit\u00e9 de Sherbrooke, Sherbrooke, Qu\u00e9bec, Canada."], ["Cicchetti", "Francesca", "F", "Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada; D\u00e9partement de Psychiatrie & Neurosciences, Facult\u00e9 de M\u00e9decine, Pavillon Ferdinand-Vandry, 1050, Ave de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada. Electronic address: Francesca.Cicchetti@crchul.ulaval.ca."], ["Calon", "Fr\u00e9d\u00e9ric", "F", "Facult\u00e9 de Pharmacie, Pavillon Ferdinand-Vandry, 1050, Avenue de la M\u00e9decine, Universit\u00e9 Laval, Qu\u00e9bec, QC, G1V 0A6, Canada; Centre de Recherche du CHU de Qu\u00e9bec-Universit\u00e9 Laval, Axe Neurosciences, 2705, Boulevard Laurier, Qu\u00e9bec, QC, G1V 4G2, Canada; OptiNutriBrain International Associated Laboratory (NutriNeuro France-INAF Canada), Canada. Electronic address: Frederic.Calon@crchul.ulaval.ca."]], "date": "2017-12-08", "id": "29229294", "text": "Polyunsaturated fatty acids omega-3 (n-3 PUFA), such as docosahexaenoic acid (DHA), have been shown to prevent, and partially reverse, neurotoxin-induced nigrostriatal denervation in animal models of Parkinson's disease (PD). However, the accumulation of \u03b1-synuclein (\u03b1Syn) in cerebral tissues is equally important to the pathophysiology. To determine whether DHA intake improves various aspects related to synucleinopathy, ninety male mice overexpressing human \u03b1Syn under the Thy-1 promoter (Thy1-\u03b1Syn) were fed one of three diets (specially formulated control, low n-3 PUFA or high DHA) and compared to non-transgenic C57/BL6 littermate mice exposed to a control diet. Thy1-\u03b1Syn mice displayed impaired motor skills, lower dopaminergic neuronal counts within the substantia nigra (-13%) in parallel to decreased levels of the striatal dopamine transporter (DAT) (-24%), as well as reduced NeuN (-41%) and synaptic proteins PSD-95 (-51%), synaptophysin (-80%) and vesicular acetylcholine transporter (VChAT) (-40%) in the cerebral cortex compared to C57/BL6 mice. However, no significant difference in dopamine concentrations was observed by HPLC analysis between Thy1-\u03b1Syn and non-transgenic C57/BL6 littermates under the control diet. The most striking finding was a favorable effect of DHA on the survival/longevity of Thy1-\u03b1Syn mice (+51% survival rate at 12months of age). However, dietary DHA supplementation did not have a significant effect on other parameters examined in this study, despite increased striatal dopamine concentrations. While human \u03b1Syn monomers and oligomers were detected in the cortex of Thy1-\u03b1Syn mice, the effects of the diets were limited to a small increase of 42kDa oligomers in insoluble protein fractions upon n-3 PUFA deprivation. Overall, our data indicate that a diet rich in n-3 PUFA has a beneficial effect on the longevity of a murine model of \u03b1-synucleinopathy without a major impact on the dopamine system and motor impairments, nor \u03b1Syn levels.", "doi": "10.1016/j.expneurol.2017.12.002", "title": "Impact of DHA intake in a mouse model of synucleinopathy.", "journal": ["Experimental neurology", "Exp. Neurol."]}